Is Increase of Homocysteine, Anti-Cardiolipin, Anti-Phospholipid Antibodies associated with Breast Tumors?
Patients with malignancy are at higher risk of thrombotic complications due to the hypercoagulability state. Our objective in this study was to assess the serum concentrations of Homocysteine, anti phospholipid antibodies, and anti cardiolipin in patients with benign and malignant breast tumors and study the effect of chemotherapy on the serum levels of these markers. A case control study was carried out on 100 women with malignant breast tumor and 100 age matched control with benign breast tumors.Serum concentrations of heomocystein, anti cardiolipin antibody (IgG and IgMaCL) and anti-phospholipid antibody (IgG and IgMaPL) were measured in all cases. The malignant group was followed for six months, and serum levels of abovementioned markers were measured again after surgical removal of breast tumor and chemotherapy. Current results showed a significantly higher serum concentration of Homocysteine, IgG and IgMaPL, IgG and IgM aCL in patients with malignant tumor before chemotherapy compared with benign tumor patients. We found a significant decrease in these markers after chemotherapy (P Value<0.05).We propose performing these tests (Homocysteine, IgG and IgM aPL, aCL) in patients with breast malignancy and starting prophylactic anti-thrombotic treatment in those with high serum levels of the markers. In addition, since the serum levels of the markers in patients with malignancy reduce after adjuvant therapies, we strongly recommend using adjuvant chemotherapy in these patients.
Scrobohaci ML. Antiphospholipid antibodies and cancer. Pathol Biol 2008;56(4):245-50.
Dobado-Barrios PM, Lopez-Pedreda C, Velazco F, et al. The role of tissue factor in the antiphospholipid syndrome. Arthritis Rhuem 2001;44(11):2467-76.
Yamashita EK, Teixeira BM, Yoshihara RN, et al. Systemic Chemotherapy Interferes in Homocysteinee Metabolism in Breast Cancer Patients. J Clin Lab Anal 2014;28(2):157-62.
Hosseini M. Role of polymorphism of methyltetrahydrofolate-Homocysteinee methyltransferase (MTR) A2756G and breast cancer risk. Pol J Pathol 2013;64(3):191-5.
Salluh JI, Soares M, De Meis E. Antiphospholipid anti bodies and multiple organ failures in critically ill cancer patients. Clinics 2009;64(2):79-82.
Yoshihara RN, Teixeira BM, Adami F, et al. Circulating tumor cell detection during chemotherapy in patients with breast cancer is not associated with plasma Homocysteinee levels. Tumour Biol 2013;34(5):2937-41.
Miesbach W, Scharrer I, Asherson RA. High titres of IgMantiphospholipid antibodies are unrelated to pathogenicity in patiens with non-Hodgkin's lymphoma. Clin Rheumatol 2007;26(1):95-7.
Schved JF, Dupuy-Fons C, Biron C, et al. A prospective epidemiological study on the occurrence of antiphospholipidantibody:the Montpellier Antiphospholipid (MAP) Study. Haemostasis 1994;24(3):175-82.
Akilzhanova A, Nurkina Z, Momynaliev K, et al. Genetic profile and determinants of Homocysteinee levels in Kazakhstan patients with breast cancer. Anticancer Res 2013;33(9):4049-59.
Den-Heijer M. HyperHomocysteineaemia as a risk factor for venous thrombosis:an update of the current evidence. Clin Chem Lab Med 2003;41(11):1404-7.
Kedzierska M, Malinowska J, Glowacki R, et al. The elevated Homocysteinee stimulates changes of haemostatic function of plasma isolated from breast cancer patients. Mol Cell Biochem 2011;355(1-2):193-9.
Miesbach W. Antiphospholipid antibodies and antiphospholipid syndrome in patients with malignancies: features, incidence, identification and treatment. Semin Thromb Hemost 2008;34(3):282-5.
Gatt A, Makris A, Cladd H, et al. Hyperhomocytsteinemia in women with advanced breast cancer. Int J lab Hematol 2008;29(6):421-5.
Lin J, Lee IM, Song Y, et al. Plasma Homocysteinee and cysteine and risk of breast cancer in women. Cancer Res 2010;70(6):2397-405.
Zhu BT. Medical hypothesis: hyper Homocysteineemia is a risk factor for estrogen-induced hormonal cancer. Int J Oncol 2003;22(3):499-508.
Kishi S, Griender J, Chang C, et al, SandlundJT.Homocysteinee pharmacogenetics,and Neurotoxicity in chidren with leukemia. J Clin Oncol 2003;21(16):3084-91.
Tincani A, Taraborelli M, Cattaneo R. Antiphospholipid antibodies and malignancies. Autoimmun Rev 2010;9(4):200-2.
Miesbach W, Scharrer I, Asherson R. Thrombotic manifestations of the antiphospholipid syndrome in patiens with malignancies. Clin Rheumatol 2006;25(6):840-4.
Gomez-puerta JA, Cervera R, Espinosa G, et al. Anti phospholipid antibodies associated with malignancies: Clinical and pathological characteristics of 120 patients. Semin Arthritis Rheum 2006;35(5):322-32.
Chou YC, Lee MS, Wu MH, et al. Plasma Homocysteinee as a metabolic risk factor for breast cancer: findings from a case-control study in Taiwan. Breast Cancer Res Treat 2007;101(2):199-205.
Zhang SM, Willett WC, Selhub J, et al. Plasma folate, vitamin B6, vitamin B12, Homocysteinee, and risk of breast cancer. J Natl Cancer Inst 2003;95(5):373-80.
Landis SH, Murray T, Bolden S, et al. Cancer Statistics 1999. CA Cancer J Clin 1999;49(1):8-31.
Tallova J, Tomandl J, Bicikova M, et al. Homocysteinee in breast cyst fluid. Eur J Clin Invest 2001;31(7):623-7.
Naess IA, Christiansen SC, Cannegieter SC, et al. A prospective study of anticardiolipin antibodies as a risk factor for venous thrombosis in a general population (the HUNT study). J Thromb Haemost 2006;4(1):44-9.